Drugs & Targets FDA approves Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma October 10, 2025Vol.51 No.37
Former NCI official’s nonprofit seeks to tell the stories of cancer patientsPatient Action for Cancer Research aims to show impact of federal research October 03, 2025Vol.51 No.36By Sara Willa Ernst
Capitol Hill U.S. government shuts downImpact on NCI uncertain as administration threatens more RIFs October 03, 2025Vol.51 No.36By Claire Marie Porter
Guest Editorial Sexual and gender minoritized cancer patients deserve better October 03, 2025Vol.51 No.36By Don S. Dizon and Binay Shah
Cancer Policy Trump signs order to use AI to accelerate pediatric cancer research October 03, 2025Vol.51 No.36By Claire Marie Porter
Cancer Policy White House announces “TrumpRx,” a new prescription drug website October 03, 2025Vol.51 No.36By Claire Marie Porter
In Brief Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research October 03, 2025Vol.51 No.36
In Brief John Turchi named inaugural chair of Department of Biochemistry, Molecular Biology and Pharmacology at IU School of Medicine October 03, 2025Vol.51 No.36
In Brief Alessio Pigazzi, expert in robot-assisted techniques, selected as new colorectal surgery leader at Cedars-Sinai October 03, 2025Vol.51 No.36
